drugset / Trial / NCT00819767

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

NCT00819767

Phase 2 Completed 68 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.

Timeline

Start
2009-02
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral
Comparator Valsartan Small molecule 320 mg Oral

Indications